Clinical trials · Riverside–San Bernardino, CA
Metastatic Breast Cancer clinical trials in Riverside–San Bernardino
We’re tracking 159 recruiting metastatic breast cancer studies with a site in or near Riverside–San Bernardino — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT06748222RecruitingPhase 3
Online mindfulness program for breast cancer survivors
This trial tests a 6-week online mindfulness program to help breast cancer survivors manage mild to moderate depression. You may qualify if you finished active treatment within the last 5 years and can use a digital device.
Riverside, CaliforniaAges 18–50 - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Riverside, CaliforniaAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Riverside, CaliforniaAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Riverside, CaliforniaAges 18–60 - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Riverside, CaliforniaAges 18 years+ - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Riverside, CaliforniaAges 18 years+ - NCT04852887RecruitingPhase 3
Testing shorter breast radiation after low-risk hormone breast cancer
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Riverside, CaliforniaAges 50–70 - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Loma Linda, CaliforniaAges 18 years+ - NCT05455619RecruitingPhase 1/Phase 2
Targeted drugs for PI3K-altered, HR+/HER2- breast cancer
This Phase 1/2 trial tests how well a combination of targeted medicines works for advanced or returning HR+/HER2- breast cancer that has a PI3K pathway change (such as PIK3CA, PTEN, or AKT1). It may help by blocking growth signals in the cancer and is especially for people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.
Loma Linda, CaliforniaAges 18 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Loma Linda, CaliforniaAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Loma Linda, CaliforniaAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Loma Linda, CaliforniaAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Redlands, CaliforniaAges 18 years+ - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Corona, CaliforniaAges 18 years+ - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Corona, CaliforniaAges 18–130 - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Corona, CaliforniaAges 18 years+ - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Upland, CaliforniaAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Upland, CaliforniaAges 18 years+ - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Yorba Linda, CaliforniaAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Orange, CaliforniaAges Any age - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Orange, CaliforniaAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Orange, CaliforniaAges 18 years+ - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Orange, CaliforniaAges 18 years+ - NCT06580002RecruitingPhase 2
Can Riluzole Help with Chemo Brain? A Pilot Study
This study tests if a medicine called riluzole (currently used for ALS) can help with 'chemo brain' – memory and thinking problems after cancer treatment. It is for people who feel their mental sharpness has declined after breast cancer therapy, certain chemotherapies, or brain radiation.
Orange, CaliforniaAges 18 years+
Hear when a new Metastatic Breast Cancer trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Metastatic Breast Cancer trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting metastatic breast cancer studies listed above.
- University of California, Irvine Medical Center / UC Irvine Health · 13 studies
- UC Irvine Health · 11 studies
- Cedars-Sinai Medical Center · 10 studies
- City of Hope Comprehensive Cancer Center · 9 studies
- USC / Norris Comprehensive Cancer Center · 9 studies
- City of Hope · 7 studies
- City of Hope Orange County Lennar Foundation Cancer Center · 7 studies
- Huntington Memorial Hospital · 6 studies
What taking part in a metastatic breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic breast cancer studies in California.
Common questions
- Are there metastatic breast cancer clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 159 recruiting metastatic breast cancer studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic breast cancer study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic breast cancer studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.